<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289792</url>
  </required_header>
  <id_info>
    <org_study_id>splitPC</org_study_id>
    <nct_id>NCT04289792</nct_id>
  </id_info>
  <brief_title>Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University Union Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel
      chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and
      locally advanced unresectable pancreatic cancer patients with sequential investigator
      selection (IC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The question of how to administer adequate chemotherapy to synchronize SBRT treatment
      strategy to maximize the benefits of neoadjuvant therapy for improved prognosis of patients
      with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer is a
      challenging and debatable issue. No studies have yet evaluated the efficacy of split-course
      SBRT as the neoadjuvant chemoradiotherapy regimen. The investigators aimed to study whether
      neoadjuvant chemotherapy plus split-course SBRT results in better outcomes in BRPC and LAPC
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">May 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of Progression-Free Survival (PFS)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Time to Treatment Failure (TTF)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>TTF was defined as the time after the first dose of study therapy to discontinuation of study therapy due to disease progression, death by any cause, or the start of a new non-protocol-defined anticancer therapy/surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>DCR was defined as the percentage of participants with a CR or PR or SD from of date of first treatment to 16 weeks. Tumor assessments after start of non-protocol-defined anticancer therapy were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>ORR was defined as the percentage of participants that achieved a combined incidence of complete (CR) and partial response (PR) using RECIST 1.1 guidelines as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Overall Survival (OS)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>Overall survival was defined as the time from the date of first dose of study therapy to the date of death (by any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From enrollment to 2 years after the end of treatment</time_frame>
    <description>TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>SBRT with concurrent chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel+Gemcitabine</intervention_name>
    <description>Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.</description>
    <arm_group_label>SBRT with concurrent chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>split-course SBRT</intervention_name>
    <description>Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).</description>
    <arm_group_label>SBRT with concurrent chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old and ≤ 70 years old.

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas.

          -  Borderline resectable or locally advanced pancreatic cancer proven by imaging
             examinations via multidisciplinary approaches according to NCCN guidelines

          -  No prior chemotherapy or radiotherapy

          -  ECOG performance status of 0 or 1.

          -  Without distant metastasis

          -  The maximum diameter of the tumor must not exceed 5 cm

          -  Acceptable hematology parameters: a. Absolute neutrophil count (ANC) ≥1500 cell/mm3 b.
             Platelet count ≥100,000/mm3 c. Hemoglobin (Hgb)≥9 g/dL

          -  Acceptable blood chemistry levels: a. AST/SGOT and ALT/SGPT≤2.5× upper limit of normal
             range (ULN) b. Total bilirubin≤1.5 ULN c. Alkaline phosphatase≤2.5× ULN d. Serum
             albumin&gt;3 g/dL e. Serum creatinine≤1.5 ULN

          -  Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures are conducted.

        Exclusion Criteria:

          -  Age ＜ 18 years old and ＞ 70 years old. Prior anticancer therapy for pancreatic
             carcinoma.

          -  Presence of or history of metastatic pancreatic adenocarcinoma.

          -  Patients who had surgeries, chemotherapy, or other treatments before inclusion.

          -  Any other malignancy within 5 years prior to enrollment

          -  History of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of
             their excipients.

          -  Peripheral sensory neuropathy Grade &gt; 1

          -  Serious medical risk factors involving any of the major organ systems, or serious
             psychiatric disorders.

          -  Pregnant or breast feeding.

          -  Patients enrolled in other clinical trials or incompliant with regular follow-up

          -  Unwillingness or inability to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benhua Xu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benhua Xu, PHD</last_name>
    <phone>+86-13696884375</phone>
    <email>benhuaxu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Zheng, PHD</last_name>
    <phone>+86 18659103321</phone>
    <email>zhengrrong@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benhua Xu, PHD</last_name>
      <email>benhuaxu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Saif MW. Pancreatic neoplasm in 2011: an update. JOP. 2011 Jul 8;12(4):316-21. Review.</citation>
    <PMID>21737886</PMID>
  </reference>
  <reference>
    <citation>Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201.</citation>
    <PMID>24104372</PMID>
  </reference>
  <reference>
    <citation>Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26. doi: 10.1245/s10434-011-1630-6. Epub 2011 Mar 10.</citation>
    <PMID>21499862</PMID>
  </reference>
  <reference>
    <citation>Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 Apr;269(4):733-740. doi: 10.1097/SLA.0000000000002600.</citation>
    <PMID>29227344</PMID>
  </reference>
  <reference>
    <citation>Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol. 2019 Mar 27;14(1):52. doi: 10.1186/s13014-019-1254-8.</citation>
    <PMID>30917842</PMID>
  </reference>
  <reference>
    <citation>Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017 Sep 15;123(18):3486-3493. doi: 10.1002/cncr.30706. Epub 2017 May 10.</citation>
    <PMID>28493288</PMID>
  </reference>
  <reference>
    <citation>Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3.</citation>
    <PMID>25734581</PMID>
  </reference>
  <reference>
    <citation>Chuong MD, Springett GM, Weber J, Klapman J, et al. Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer. Journal of Radiation Oncology. 2012;1:273-281</citation>
  </reference>
  <reference>
    <citation>Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010 Aug;17(8):2092-101. doi: 10.1245/s10434-010-1019-y. Epub 2010 Mar 12.</citation>
    <PMID>20224860</PMID>
  </reference>
  <reference>
    <citation>Rombouts SJ, Walma MS, Vogel JA, van Rijssen LB, Wilmink JW, Mohammad NH, van Santvoort HC, Molenaar IQ, Besselink MG. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2016 Dec;23(13):4352-4360. Epub 2016 Jul 1. Review.</citation>
    <PMID>27370653</PMID>
  </reference>
  <reference>
    <citation>Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.</citation>
    <PMID>25564157</PMID>
  </reference>
  <reference>
    <citation>Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.</citation>
    <PMID>25538019</PMID>
  </reference>
  <reference>
    <citation>Kharofa J, Mierzwa M, Olowokure O, Sussman J, Latif T, Gupta A, Xie C, Patel S, Esslinger H, Mcgill B, Wolf E, Ahmad SA. Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer. Am J Clin Oncol. 2019 Mar;42(3):247-252. doi: 10.1097/COC.0000000000000518.</citation>
    <PMID>30724781</PMID>
  </reference>
  <reference>
    <citation>Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303. doi: 10.1016/j.ijrobp.2016.05.010. Epub 2016 May 24.</citation>
    <PMID>27475674</PMID>
  </reference>
  <reference>
    <citation>Bae SH, Kim MS, Kim SY, Jang WI, Cho CK, Yoo HJ, Kim KB, Lee DH, Han CJ, Yang KY, Kim SB. Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int J Colorectal Dis. 2013 Dec;28(12):1707-13. doi: 10.1007/s00384-013-1717-6. Epub 2013 Jun 18.</citation>
    <PMID>23775098</PMID>
  </reference>
  <reference>
    <citation>Rostom AY, Tahir S, Gershuny AR, Kandil A, Folkes A, White WF. Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):289-92.</citation>
    <PMID>8635935</PMID>
  </reference>
  <reference>
    <citation>McLaren DB, Morrey D, Mason MD. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol. 1997 May;43(2):171-4.</citation>
    <PMID>9192963</PMID>
  </reference>
  <reference>
    <citation>Scholten AN, Leer JW, Collins CD, Wondergem J, Hermans J, Timothy A. Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol. 1997 May;43(2):163-9.</citation>
    <PMID>9192962</PMID>
  </reference>
  <reference>
    <citation>Jose CC, Price A, Norman A, Jay G, Huddart R, Dearnaley DP, Horwich A. Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol (R Coll Radiol). 1999;11(5):330-3.</citation>
    <PMID>10591821</PMID>
  </reference>
  <reference>
    <citation>Hafeez S, McDonald F, Lalondrelle S, McNair H, Warren-Oseni K, Jones K, Harris V, Taylor H, Khoo V, Thomas K, Hansen V, Dearnaley D, Horwich A, Huddart R. Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):532-533.</citation>
    <PMID>28586948</PMID>
  </reference>
  <reference>
    <citation>Bledsoe TJ, Noble AR, Reddy CA, Burkey BB, Greskovich JF, Nwizu T, Adelstein DJ, Saxton JP, Koyfman SA. Split-Course Accelerated Hypofractionated Radiotherapy (SCAHRT): A Safe and Effective Option for Head and Neck Cancer in the Elderly or Infirm. Anticancer Res. 2016 Mar;36(3):933-9.</citation>
    <PMID>26976981</PMID>
  </reference>
  <reference>
    <citation>Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.</citation>
    <PMID>27160474</PMID>
  </reference>
  <reference>
    <citation>Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017 Jun;8(3):566-571. doi: 10.21037/jgo.2017.02.02.</citation>
    <PMID>28736643</PMID>
  </reference>
  <reference>
    <citation>Verma V, Lazenby AJ, Zheng D, Bhirud AR, Ly QP, Are C, Sasson AR, Lin C. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol. 2017 Mar;122(3):464-469. doi: 10.1016/j.radonc.2016.12.030. Epub 2017 Jan 12.</citation>
    <PMID>28089484</PMID>
  </reference>
  <reference>
    <citation>Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. Erratum in: Med Phys. 2012 Jan;39(1):563. Dosage error in article text.</citation>
    <PMID>20879569</PMID>
  </reference>
  <reference>
    <citation>Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019 Jan 8;19(1):40. doi: 10.1186/s12885-018-5244-2.</citation>
    <PMID>30621618</PMID>
  </reference>
  <reference>
    <citation>Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2019 Aug;270(2):340-347. doi: 10.1097/SLA.0000000000002753.</citation>
    <PMID>29596120</PMID>
  </reference>
  <reference>
    <citation>Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705.</citation>
    <PMID>29462005</PMID>
  </reference>
  <reference>
    <citation>Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol. 2017 May;24(5):1406-1413. doi: 10.1245/s10434-016-5707-0. Epub 2016 Nov 28.</citation>
    <PMID>27896518</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016 Apr;57:10-22. doi: 10.1016/j.ejca.2015.12.026. Epub 2016 Feb 4. Review.</citation>
    <PMID>26851397</PMID>
  </reference>
  <reference>
    <citation>Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6. doi: 10.1016/j.ijrobp.2009.09.075. Epub 2010 Apr 14.</citation>
    <PMID>20399033</PMID>
  </reference>
  <reference>
    <citation>Paik EK, Kim MS, Seo YS, Jang WI, Kang JK, Cho CK, Yoo HJ. Feasibility of split-course stereotactic ablative radiotherapy for oligometastases. Jpn J Clin Oncol. 2018 Jun 1;48(6):548-554. doi: 10.1093/jjco/hyy062.</citation>
    <PMID>29722825</PMID>
  </reference>
  <reference>
    <citation>Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.</citation>
    <PMID>21532501</PMID>
  </reference>
  <reference>
    <citation>Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):12-26. Review.</citation>
    <PMID>10210536</PMID>
  </reference>
  <reference>
    <citation>Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999 Jan 1;59(1):107-14.</citation>
    <PMID>9892194</PMID>
  </reference>
  <reference>
    <citation>Higuchi Y, Serizawa T, Nagano O, Matsuda S, Ono J, Sato M, Iwadate Y, Saeki N. Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1543-8. doi: 10.1016/j.ijrobp.2008.10.035. Epub 2009 Jan 8.</citation>
    <PMID>19135317</PMID>
  </reference>
  <reference>
    <citation>Hsieh CH, Chang HT, Lin SC, Chen YJ, Wang LY, Hsieh YP, Chen CA, Chong NS, Lin SL, Chen CY, Shueng PW. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report. BMC Cancer. 2010 Dec 31;10:696. doi: 10.1186/1471-2407-10-696.</citation>
    <PMID>21194444</PMID>
  </reference>
  <reference>
    <citation>Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22.</citation>
    <PMID>28937324</PMID>
  </reference>
  <reference>
    <citation>Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1188-95. doi: 10.1016/j.ijrobp.2010.10.007. Epub 2010 Dec 22.</citation>
    <PMID>21183291</PMID>
  </reference>
  <reference>
    <citation>Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):254-62. doi: 10.1016/j.ijrobp.2013.07.022. Review.</citation>
    <PMID>24411596</PMID>
  </reference>
  <reference>
    <citation>Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012 Mar;177(3):311-27. Epub 2012 Jan 9. Review.</citation>
    <PMID>22229487</PMID>
  </reference>
  <reference>
    <citation>Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011;2011:439752. doi: 10.1155/2011/439752. Epub 2011 Nov 15. Review.</citation>
    <PMID>22162711</PMID>
  </reference>
  <reference>
    <citation>Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014 Aug;19(4):570-8. doi: 10.1007/s10147-014-0717-z. Epub 2014 Jul 5. Review.</citation>
    <PMID>24993673</PMID>
  </reference>
  <reference>
    <citation>Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res. 2015 Aug 15;21(16):3727-39. doi: 10.1158/1078-0432.CCR-14-2824. Epub 2015 Apr 13.</citation>
    <PMID>25869387</PMID>
  </reference>
  <reference>
    <citation>Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009 Jul 16;114(3):589-95. doi: 10.1182/blood-2009-02-206870. Epub 2009 Apr 6.</citation>
    <PMID>19349616</PMID>
  </reference>
  <reference>
    <citation>Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15;174(12):7516-23.</citation>
    <PMID>15944250</PMID>
  </reference>
  <reference>
    <citation>Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429. Review.</citation>
    <PMID>20518016</PMID>
  </reference>
  <reference>
    <citation>Aryankalayil MJ, Makinde AY, Gameiro SR, Hodge JW, Rivera-Solis PP, Palayoor ST, Ahmed MM, Coleman CN. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res. 2014 Aug;182(2):139-48. doi: 10.1667/RR13731.1. Epub 2014 Jul 8.</citation>
    <PMID>25003313</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University Union Hospital</investigator_affiliation>
    <investigator_full_name>Benhua Xu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

